HemoSonics first product will be a rapid, easy to use, easy to interpret Point-of-Care (POC) analyzer to fully characterize and guide the management of hemostasis disorders, tying its diagnostics outputs directly to available medical interventions. This instrument can measure the entire hemostatic process, including the functional role of the coagulation factors, the cellular components, and the fibrinolytic proteins. Global assessment of hemostasis is critically needed to guide patient care in the operating room, labor and delivery room, emergency department, trauma centers, the battlefield, and a variety of other clinical settings.
Each test is performed using a disposable cartridge that is pre-loaded with lyophilized reagents. No pipetting or measuring will be required. A library of disposable cartridges will be available to the user.
Additional products are currently in the pipeline.
HemoSonics’ products are based on an innovative and patented technology named sonorheometry. Sonorheometry uses the phenomenon of acoustic radiation force to characterize the dynamic changes in viscoelastic properties of whole blood during coagulation and clot lysis. This technology is expected to provide significant advantages over competitive products. Sonorheometry is particularly advantageous compared to other devices because it can perform measurements without any moving mechanical part and it can be implemented in compact, readily available electronics. This potential for miniaturization is also critical to design and manufacture an instrument that has a small footprint, is lightweight, and at the point of care.
HemoSonics’ products are currently not approved by the US Food and Drug Administration. Product development is performed in collaboration with StarFish Medical (Victoria, BC).
